




The relative strengths and weaknesses of Summit Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Summit Therapeutics Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 78%, being 135% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	189,712
Cost of Goods Sold	0
Intangible Assets	1,893
Liabilities, Current	20,405
Liabilities, Non-Current	4,852
Other Assets	11,140
Other Compr. Net Income	-555
Other Expenses	520,915
Other Liabilities	100,000
Other Net Income	-4,277
Other Revenues	0
Property and Equipment	204
Research and Development	59,471
Selling, General and Administrative Expense	30,265

Output Variable	Value in 1000 USD
Assets	202,949
Liabilities	125,257
Expenses	610,651
Revenues	0
Stockholders Equity	77,692
Net Income	-614,928
Comprehensive Net Income	-615,206
BaseVar	471,844
ECR before LimitedLiability	-272%
Economic Capital Ratio	78%